5 Topic Commentaries

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

• 

  Isabelle Rivière, PhD

  Cell and gene therapy manufacturing

  •

  Memorial Sloan Kettering Cancer Center

  In my view, it is not possible to expand applications and access without automation and digital monitoring of the operation.

  Source
• 

  Jae Park, MD

  Hematologic oncology and cellular therapy

  •

  Memorial Sloan Kettering Cancer Center

  If the cells are more potent and last longer, we ultimately would need fewer of them, which could make manufacturing easier and less expensive.

  Source
• 

  Peter Marks, MD, PhD

  Regulatory science for biologics and CGT

  •

  U.S. Food and Drug Administration

  Adeno-associated viral vectors cannot be made at scale that could treat tens of thousands of people. That's not currently possible.

  Source
• 

  Laurie H. Glimcher, MD

  Oncology and immunology leadership

  •

  Dana-Farber Cancer Institute

  By bringing together the talent that exists only in the Massachusetts life sciences ecosystem and fostering collaboration, this new manufacturing center will help to extend the benefit of these technologies to more patients and accelerate discoveries to effectively treat more diseases.

  Source
• 

  Leonard Zon, MD

  Stem cell biology and regenerative medicine

  •

  Boston Children's Hospital

  For academic investigators who want to see their basic science advance into the clinic space, it’s important to have a manufacturing facility collaborate on protocols. Researchers can then exchange information directly with the facility, optimizing protocols and working smarter.

  Source